US4493702A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Parenteral administration using osmotically motivated delivery system
Assignee: Alza Corp
•
Filing: 1983-10-17
•
Granted: 1985-01-15
•
Expires: 2003-10-17
Abstract
Abstract A parenteral delivery set is disclosed for administering a beneficial agent to a recipient. The set comprises (a) a primary container of a medical fluid; (b) a primary tubing in fluid communication with the primary container; (c) a secondary container of a medical fluid; (d) a secondary tubing in fluid communication with the secondary container; (e) a formulation chamber connected to the secondary tubing and housing an agent dispensing device or the beneficial agent; and (f) a common tubing in communication with the primary tubing and the secondary tubing for communicating the set to the recipient.
Inventors
- 👤 John Urquhart
- 👤 Felix Theeuwes
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 10:54
CPC Classifications
A; A61; A61M; A61M5/00; A61M5/14; A61M5/1407; A61M5/142; A61M5/145; A61M2005/14513
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
192 words
A parenteral delivery set for administering a beneficial agent formulation to a warm-blooded animal, the delivery set comprising: (a) a primary tube for the flow of a parenterally acceptable fluid therethrough; (b) a secondary tube for the flow of a parenterally acceptable fluid therethrough; (c) a formulation chamber having means for establishing communication with the secondary tube, the formulation chamber comprising: (1) a wall that surrounds an internal lumen; (2) an inlet in the wall for letting a parenterally acceptable fluid enter the formulation chamber; (3) a beneficial agent osmotic delivery device in the formulation chamber, the delivery device comprising: (i) a wall formed of a semipermeable composition that surrounds and forms a compartment, (ii) a beneficial agent in the compartment, and (iii) a passageway in the wall of the delivery device connecting the compartment with the formulation chamber; (4) an outlet in the wall for letting an agent formulation leave the formulation chamber; (d) a common tube having means for communicating with the primary tube for receiving parenterally acceptable fluid from the primary tube, and for communicating with the secondary tube for receiving parenterally administrable agent formulation from the secondary tube.
Claim 2
Dependent Claim
192 words
A parenteral delivery set for administering a beneficial agent formulation to a warm-blooded animal, the delivery set comprising: (a) a primary tube for the flow of a parenterally acceptable fluid therethrough; (b) a secondary tube for the flow of a parenterally acceptable fluid therethrough; (c) a formulation chamber having means for establishing communication with the secondary tube, the formulation chamber comprising: (1) a wall that surrounds an internal lumen; (2) an inlet in the wall for letting a parenterally acceptable fluid enter the formulation chamber; (3) a beneficial agent osmotic delivery device in the formulation chamber, the delivery device comprising: (i) a wall formed of a semipermeable composition that surrounds and forms a compartment, (ii) a beneficial agent in the compartment, and (iii) a passageway in the wall of the delivery device connecting the compartment with the formulation chamber; (4) an outlet in the wall for letting an agent formulation leave the formulation chamber; (d) a common tube having means for communicating with the primary tube for receiving parenterally acceptable fluid from the primary tube, and for communicating with the secondary tube for receiving parenterally administrable agent formulation from the secondary tube.
Claim 3
Dependent Claim
29 words
The parenteral delivery set for administering the beneficial agent formulation according to claim 1, wherein the formulation chamber is replaced each time the device has delivered the beneficial agent.
Claim 4
Dependent Claim
23 words
The parenteral delivery set for administering the beneficial agent formulation according to claim 1, wherein the beneficial agent is an intravenously administrable drug.
References Cited (Backward Citations)
US3305446A
Cited
CH497181A
Cited
US3854480A
Cited
US3993073A
Cited
US3797494A
Cited
US3995631A
Cited
US3756237A
Cited
US3760984A
Cited
US3948254A
Cited
US3845770A
Cited
US3921636A
Cited
US4177256A
Cited
US3941126A
Cited
US3993072A
Cited
US4217894A
Cited
US4233973A
Cited
US4219022A
Cited
US4256104A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-01-15 | 1988-07-16 | 1989-01-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-01-15 | 1992-07-16 | 1993-01-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-01-15 | 1996-07-16 | 1997-01-15 | $7700.00 | Window Closed / Lapsed |